Skip to main content

USPSTF: Evidence Lacking for Interventions to Prevent Child Maltreatment

Medically reviewed by Carmen Pope, BPharm. Last updated on March 19, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, March 19, 2024 -- The current evidence is insufficient for assessing the balance of benefits and harms of interventions in primary care for preventing child maltreatment. These findings form the basis of a final recommendation statement published in the March 19 issue of the Journal of the American Medical Association.

Meera Viswanathan, Ph.D., from the RTI-International-University of North Carolina at Chapel Hill Evidence-based Practice Center, and colleagues reviewed the evidence on primary care-feasible or referable interventions to prevent child maltreatment in a review including 25 trials with 14,355 participants. The researchers found that evidence from 11 studies with 5,311 participants indicated there were no differences in the likelihood of reports to Child Protective Services within one year of intervention completion; five studies with 3,336 participants found no differences in removal of the child from the home within one to three years of follow-up. No benefits were seen for emergency department visits in the short-term (under two years) and hospitalizations. For all other outcomes, the evidence was inconclusive. Neither of the two trials reporting harms indicated statistically significant differences.

Based on these findings, the USPSTF concludes that in children and adolescents younger than 18 years without signs or symptoms of a known exposure to maltreatment, the current evidence is inadequate for determining the balance of benefits and harms of primary care interventions to prevent child maltreatment (I statement).

"There is still not enough evidence on what can be done in primary care to prevent maltreatment before it occurs," USPSTF member James Stevermer, M.D., said in a statement. "The task force continues to urgently call for more research in this area."

Evidence Report

Final Recommendation Statement

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Allergy-Related Psychological Distress Common

TUESDAY, July 2, 2024 -- Psychological distress related to food allergies (FA) is common globally, according to a study published online June 21 in Allergy. Rebecca C...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.